Cargando…

The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile

BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism...

Descripción completa

Detalles Bibliográficos
Autores principales: Börgel, Jan, Bulut, Daniel, Hanefeld, Christoph, Neubauer, Horst, Mügge, Andreas, Epplen, Jörg T, Holland-Letz, Tim, Spiecker, Martin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626571/
https://www.ncbi.nlm.nih.gov/pubmed/19105833
http://dx.doi.org/10.1186/1471-2261-8-41
_version_ 1782163450926989312
author Börgel, Jan
Bulut, Daniel
Hanefeld, Christoph
Neubauer, Horst
Mügge, Andreas
Epplen, Jörg T
Holland-Letz, Tim
Spiecker, Martin
author_facet Börgel, Jan
Bulut, Daniel
Hanefeld, Christoph
Neubauer, Horst
Mügge, Andreas
Epplen, Jörg T
Holland-Letz, Tim
Spiecker, Martin
author_sort Börgel, Jan
collection PubMed
description BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we investigated the influence of this polymorphism on survived myocardial infarction in two study groups of patients with on average high cardiovascular risk profile. METHODS: The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by allele specific restriction and light cycler analysis. RESULTS: The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N = 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026, odds ratio 1.73, 95%-CI [1.06–2.83]). In the multivariate logistic regression analysis the odds ratio for a history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957–2.731] but this trend was not significant (p = 0.073). CONCLUSION: In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the development of myocardial infarction. However, since our result is close to the border of significance, this question should be clarified in larger, prospective studies in the future.
format Text
id pubmed-2626571
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26265712009-01-15 The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile Börgel, Jan Bulut, Daniel Hanefeld, Christoph Neubauer, Horst Mügge, Andreas Epplen, Jörg T Holland-Letz, Tim Spiecker, Martin BMC Cardiovasc Disord Research Article BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolises arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we investigated the influence of this polymorphism on survived myocardial infarction in two study groups of patients with on average high cardiovascular risk profile. METHODS: The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by allele specific restriction and light cycler analysis. RESULTS: The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N = 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026, odds ratio 1.73, 95%-CI [1.06–2.83]). In the multivariate logistic regression analysis the odds ratio for a history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957–2.731] but this trend was not significant (p = 0.073). CONCLUSION: In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the development of myocardial infarction. However, since our result is close to the border of significance, this question should be clarified in larger, prospective studies in the future. BioMed Central 2008-12-23 /pmc/articles/PMC2626571/ /pubmed/19105833 http://dx.doi.org/10.1186/1471-2261-8-41 Text en Copyright © 2008 Börgel et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Börgel, Jan
Bulut, Daniel
Hanefeld, Christoph
Neubauer, Horst
Mügge, Andreas
Epplen, Jörg T
Holland-Letz, Tim
Spiecker, Martin
The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title_full The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title_fullStr The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title_full_unstemmed The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title_short The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile
title_sort cyp2j2 g-50t polymorphism and myocardial infarction in patients with cardiovascular risk profile
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626571/
https://www.ncbi.nlm.nih.gov/pubmed/19105833
http://dx.doi.org/10.1186/1471-2261-8-41
work_keys_str_mv AT borgeljan thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT bulutdaniel thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT hanefeldchristoph thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT neubauerhorst thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT muggeandreas thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT epplenjorgt thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT hollandletztim thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT spieckermartin thecyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT borgeljan cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT bulutdaniel cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT hanefeldchristoph cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT neubauerhorst cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT muggeandreas cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT epplenjorgt cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT hollandletztim cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile
AT spieckermartin cyp2j2g50tpolymorphismandmyocardialinfarctioninpatientswithcardiovascularriskprofile